What is Varicella Zoster Vaccine Antigen?
Varicella Zoster Vaccine Antigen (VZVA) is a vaccine used to prevent Shingles and varicella. Its main component is the antigen of Varicella Zoster Virus (VZV) with virus immunogenicity. The vaccine is produced by the expression system of Icterobacter flavus, and consists of three Viral protein expressed by Icterobacter flavus: gpE, gpI and gpII.
The structure of Varicella Zoster Vaccine Antigen
The structure of VZVA is a complex composed of three viral proteins: gpE, gpI and gpII. These proteins contain immunogen determinants (epitopes), which are key structures that can be recognized by the human immune system identification and generate antibody responses.
The history of Varicella Zoster Vaccine Antigen
The development history of VZVA can be traced back to the 1960s, when it was developed as a vaccine for treating chickenpox. However, since the vaccine may cause Shingles to reoccur in adults, the purpose of the vaccine was later turned to prevent Shingles.
At present, VZVA is part of the routine vaccine plans of many countries, including the United States, Canada, Japan and some European countries. VZVA can be administered to patients through injection or oral administration. Early Varicella vaccine is recommended for children aged 1 year and below, and for young children and adults due to the risk of virus infection.
The function of Varicella Zoster Vaccine Antigen
The main function of VZVA is to prevent Shingles and chickenpox. Shingles is a kind of viral infection, which is characterized by rash and pain, mainly affecting the elderly, and posing a threat to their health and quality of life. Chickenpox is also a viral infection that typically occurs in early childhood, but can also affect adults. Although the symptoms of chickenpox are usually mild, in some cases, it may lead to serious complications such as pneumonia and encephalitis.
The mechanism of Varicella Zoster Vaccine Antigen
The mechanism of action of VZVA involves the response of the human immune system. When a person is vaccinated with VZVA, the vaccine simulates a true viral infection, prompting the body to produce an immune response and generate antibodies to enhance immunity. When vaccinators encounter the actual VZV virus, their immune system can produce and release antibodies more quickly and effectively, thereby preventing the occurrence of diseases.
VZVA related drugs
At present, there are many vaccines on the market to prevent Shingles and chickenpox. The two most commonly used vaccines are Varivax and Zostavax. Varivax is a Varicella vaccine for children, while Zostavax is a Zoster vaccine for adults. In addition, with the gradual deepening of research on VZVA, there may be more related drugs available in the future.
